| Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules (NCT06215885) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-22 |
| Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer (NCT06229067) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-19 |
| Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (NCT06197581) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-12 |
| Toripalimab for High-risk Locally Advanced Cervical Cancer (NCT06416696) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-09 |
| Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) (NCT06198907) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-01 |
| Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy (NCT06649565) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-01 |
| Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC (NCT06345287) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-01 |
| Quantitative Nodal Burden as a Determinant Identifying Ampullary Adenocarcinoma Patients Benefiting From Adjuvant Chemotherapy (NCT06435767) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-01 |
| Hypofractionated Radiotherapy for HNSCC in Elderly Patients (NCT06768125) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2024-01-01 |
| ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer (NCT06543836) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-12-01 |
| NV-001 in the Treatment of Advanced Solid Tumors (NCT06051760) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-12-01 |
| Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC (NCT06170710) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-12-01 |
| Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H) (NCT06146946) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-12-01 |
| Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients (NCT06149533) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-11-30 |
| Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer (NCT06156761) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-11-28 |
| Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection (NCT06189183) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-11-11 |
| Personalized KSX01-TCRT in Patients With Advanced Solid Tumors (NCT06150365) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-11-07 |
| Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer (NCT06154538) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-11-01 |
| Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy (NCT06084897) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-10-16 |
| A Study to Observe and Evaluate the Safety and Efficacy of c610 Injection for Treatment of Advanced Solid Tumor Patients (NCT06082570) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-10-01 |
| A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients (NCT06082557) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-10-01 |
| 68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC (NCT06277180) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-10-01 |
| An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors (NCT06038461) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-09-15 |
| A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer (NCT06074484) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-09-10 |
| Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection (NCT06115837) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-09-01 |
| Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer (NCT05983094) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-09-01 |
| Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer (NCT06135571) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-09-01 |
| SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC (NCT06457906) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-09-01 |
| Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer (NCT05730595) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-09-01 |
| The Sequential Combination of FOLFOX and Toripalimab for Perioperative Immuno-Oncology Therapy of HER2-negative Adenocarcinoma of the Esophagogastric Junction (Siewert I/II): (NCT05986227) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-08-01 |
| The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC (NCT05904015) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-08-01 |
| Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer (NCT05983107) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-07-20 |
| XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC (NCT05970302) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-07-07 |
| LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer (NCT05886439) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-05-11 |
| 68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer (NCT06084767) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-05-05 |
| Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03) (NCT05938374) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-05-01 |
| Applications of Fluorescence Imaging Guided Lymph Node Dissection and Fluorescence Angiography of Inferior Mesenteric Artery Assisted Left Colic Artery Preservation (NCT06033794) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-05-01 |
| MSLN-targeted CAR-T Cells in Solid Tumors. (NCT05783089) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-04-01 |
| Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer (NCT05815290) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-03-29 |
| XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer (NCT05815303) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-03-29 |
| Efficacy and Safety of Concurrent Chemoradiotherapy With Oral Vinorelbine in Patients With Non-small Cell Lung Cancer (NCT06540950) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-03-20 |
| Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma (NCT06410651) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-03-01 |
| Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients (NCT06429839) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-03-01 |
| Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma (NCT06170697) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-03-01 |
| Transhiatal Tunnel Valvuloplasty for Reconstruction Following the Laparoscopic Proximal Gastrectomy (NCT06354036) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-03-01 |
| RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody (NCT06481553) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-02-01 |
| Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma (NCT06540508) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-02-01 |
| Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer (NCT06114420) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-01-30 |
| Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC (NCT05888402) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-01-20 |
| Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins (NCT05749302) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-01-08 |
| Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy (NCT05777824) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-01-01 |
| Multivisceral Radical Resection for Surgical T4b Colorectal Cancer: Propensity Score-matched Study Comparing the the Laparoscopic and Open Approaches (NCT05707598) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-01-01 |
| To Explore the Protective Effect of SARS-CoV-2 Vaccination on Cancer Patients Infected With SARS-CoV-2 (NCT05774171) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-01-01 |
| MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer (NCT07156058) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-01-01 |
| Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression (NCT05749289) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-12-20 |
| Additional Consolidative Esophagectomy for the Patients With Oligometastatic Resectable ESCC (NCT05951127) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-11-01 |
| Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer (NCT05747313) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-11-01 |
| Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients (NCT05762900) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-10-25 |
| Application of 18F-PSMA PET / CT Imaging in Prostate Specific Membrane Antigen Positive Tumor (NCT05761366) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-10-13 |
| Perioperative Analgesia Modes in Minimally Invasive Esophagectomy (NCT05504265) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-10-10 |
| Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients (NCT06202001) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-10-01 |
| A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis (NCT06048146) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-10-01 |
| Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer (NCT05542680) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-09-30 |
| Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients (NCT05443646) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-09-23 |
| Mechanical Bowel Preparation Versus no Bowel Preparation for Esophageal Cancer Surgery (NCT05523960) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-09-01 |
| Fractionated Stereotactic Radiotherapy for Limited Small Volume Brain Metastases (NCT07405047) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-09-01 |
| Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma (NCT06163729) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-08-25 |
| Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma (NCT06087068) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-08-01 |
| Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC (NCT05541445) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-08-01 |
| Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients (NCT06403709) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-08-01 |
| Deep Learning-based Classification and Prediction of Radiation Dermatitis in Head and Neck Patients (NCT05607225) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-07-01 |
| A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer (NCT06082180) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-07-01 |
| Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma (NCT06644352) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-07-01 |
| Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer (NCT05497739) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-06-28 |
| A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN) (NCT05603078) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-06-21 |
| The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis (NCT05431504) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-06-01 |
| ABOD2011 in Patients With Advanced Solid Tumors Progressed After Standard Systemic Therapy (NCT05392699) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-05-25 |
| Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma (NCT05385926) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-05-05 |
| Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma (NCT05540145) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-05-01 |
| Early Screening of Colorectal Cancer Based on Plasma Multi-omics Combining With Artificial Intelligence (NCT05587452) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-05-01 |
| Super-Hypofractionated Partial Breast Irradiation (NCT06615466) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-04-22 |
| Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 (NCT05289726) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-04-18 |
| Surgery or Chemoradiotherapy for Cervical Esophageal Cancer (NCT05327517) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-04-10 |
| A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway (NCT05331326) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-04-01 |
| Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer (NCT05345860) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-03-24 |
| Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Biopsy in Early Stage Cervical Cancer (NCT05167149) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-02-01 |
| A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer (NCT05681728) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-02-01 |
| A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy (NCT05511051) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-02-01 |
| Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC (NCT05974007) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-01-01 |
| Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01) (NCT05224934) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-01-01 |
| Oral Vinorelbine and Capecitabine in Advanced HER2-negative Breast Cancer (NCT05747326) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2022-01-01 |
| A Study of Tislelizumab, Chemotherapy, and Radiation Therapy for Early-Stage High-Risk ENKTCL (CLCG-2102) (NCT05254899) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-11-10 |
| Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer (NCT05749016) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-11-01 |
| Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） (NCT05235100) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-09-01 |
| Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma (NCT05448885) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-09-01 |
| Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases (NCT06611657) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-08-20 |
| Multi-center Study of Deep Learning AI in Breast Mass (NCT05443672) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-08-12 |
| Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment (NCT04970043) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-07-31 |
| SBRT With DIBH for HCC After TACE and Lipiodol Marking (NCT05021250) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-07-21 |
| A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy (NCT04972201) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-06-01 |